Description: This article discusses the closed nature of the Brazilian reinsurance market due to the IRB. The Instituto de Resseguros do Brasil is owned 50% by the 15 insurance companies that are licensed to do business in Brazil and 50% by the Government of Brazil, but the Government owns 100% of the voting shares. All reinsurance business must be transacted with and via the IRB. The process, opportunities and risks associated with this scheme are explored.

Description: This article enumerates many important considerations for a managing general underwriter(MGU) desiring to contract with an insurance carrier to issue and service provider excess of loss policies covering catastrophic medical risks assumed by accountable care organizations (ACOs).

Description: Medical insurance today is more like pre-paid medical payments. Medical insurance should be bought for protection, but rarely used, like auto insurance.

Description: Four appendices are attached to the monograph: a letter requesting information, two letters requesting participation, and a set of general database specifications. From Group Medical Insurance Large Claims Database Collections and Analysis, M-HB97-1.

Description: The rapid pace of change within the reinsurance sector over the past few years has given way to the permutations of a “new reality” that is being shaped by abundant capacity from traditional and alternative sources.

Description: The impact of benefit design on the cost of Aggregate Stop-Loss Coverage. Issue No. 42.

Description: Chapter 6 analyzes, in table form, the study's hospital and non-hospital charges and claimant counts in relation to deductible and broken down by plan design type. From Group Medical Insurance Large Claims Database Collection and Analysis, M-HB97-1.

Description: LEARN is an offering to regulators about reinsurance. This article summarizes a session held for Brazilian health regulators in the fall of 2022.

Description: This article attempts to make a modest contribution to the dialogue on the potential and risks associated with novel treatments such as cell & gene therapies. With a fast-expanding roster of what are believed to be one-time treatments at ever increasing price points aimed at curing a wider swatch of the population, they are as much a source of relief for patients stuck in medical limbo, as they are a source of anxiety for payers.